All In Biotech

Drug Trial Radar · NCT06710184

Treatment With Aspirin Alone Versus Aspirin in Combination With Fondaparinux Before Early Coronary Assessment in Patients With Non-ST-Elevation Myocardial Infarction

Aspirin Versus Aspirin and Fondaparinux Prior to Early Invasive Strategy in Patients With NSTEMI

Last checked: Nov 20, 2026Latest source record: May 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 5,076 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

5,076

Planned (sponsor's estimate)

Start

May 1, 2025

Primary completion

Jan 1, 2029

Study completion Jul 1, 2029

Sponsor

Lead sponsor
University of AarhusAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Danske Regioner; Aalborg University Hospital; Odense University Hospital; Copenhagen University Hospital, Rigshospitalet; Randers Regional Hospital; Viborg Regional Hospital; Gødstrup Hospital; Sydvestjysk Hospital Esbjerg; Lillebaelt Hospital, Kolding and Vejle, Denmark; Hospital of Southern Jutland; Horsens Hospital
First posted
Nov 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main goal of this study is to compare two treatments in patients with a specific type of heart attack called Non-ST-elevation Myocardial Infarction (NSTEMI). The investigators want to find out whether using aspirin alone is as effective and safer than using aspirin together with a second blood thinner called fondaparinux. Both treatments will be given before a scheduled heart procedure called coronary angiography (CAG), which may include balloon dilation and stent placement (PCI) if needed. The current guidelines recommend using aspirin in combination with a second blood thinner like fondaparinux before CAG and possible PCI. However, these recommendations are based on studies from the 1990s, a time when invasive procedures were not standard practice for these patients. In contrast, nearly all patients with NSTEMI in Denmark (96%) now undergo CAG within 72 hours. This change in practice raises questions about whether the older studies still provide a valid foundation for today's guidelines. The study aims to answer two questions: 1. Is aspirin alone as effective as aspirin combined with fondaparinux before early CAG and possible PCI? 2. Is aspirin alone safer, with a lower risk of severe bleeding, compared to the combination treatment? To answer these questions, the investigators will enroll about 5,000 patients with NSTEMI. Participants will be randomly assigned to receive either aspirin alone or aspirin with fondaparinux. The investigators will monitor them for 30 days to compare outcomes such as death, new heart attacks, the need for urgent CAG before the scheduled, and severe bleeding.

Conditions

  • NSTEMI - Non-ST Segment Elevation Myocardial Infarction (MI)
  • Acute Myocardial Infarction (AMI)

Interventions

  • AspirinDrug

    Aspirin bolus of 300 mg followed by 75 mg daily until CAG

  • Fondaparinux SodiumDrug

    Fondaprinux 2.5 mg subcutaneus daily until CAG (1.5 mg for patients with eGFR 20-50 ml/min/1.73m2)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite endpoint of mortality, new myocardial infarction, and clinical deterioration resulting in acute CAGTime frame: The primary endpoints will be assessed after day 30.

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Aarhus University Hospital, Department of Cardiology

    Aarhus N, Denmark · Recruiting

  • Regionshospitalet Gødstrup

    Herning, Region Midt, Denmark · Recruiting

  • Regionshospitalet Horsens

    Horsens, Region Midt, Denmark · Not yet recruiting

  • Regionshospitalet Viborg

    Viborg, Region Midt, Denmark · Recruiting

  • Aalborg Universitetshospital

    Aalborg, Region Nord, Denmark · Not yet recruiting

  • Sygehus Søndejylland, Aabenraa

    Aabenraa, Region Syd, Denmark · Recruiting

  • Esbjerg Sygehus

    Esbjerg, Region Syd, Denmark · Not yet recruiting

  • Sygehus Lillebælt, Kolding

    Kolding, Region Syd, Denmark · Recruiting

  • Odense Universitetshospital

    Odense, Region Syd, Denmark · Recruiting

  • Sygehus Lillebælt, Vejle

    Vejle, Region Syd, Denmark · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.